High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays

被引:1532
作者
Pinkel, D
Seagraves, R
Sudar, D
Clark, S
Poole, I
Kowbel, D
Collins, C
Kuo, WL
Chen, C
Zhai, Y
Dairkee, SH
Ljung, BM
Gray, JW
Albertson, DG
机构
[1] Univ Calif San Francisco, Ctr Canc, Canc Genet Program, San Francisco, CA 94143 USA
[2] Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA
[3] Vysis Inc, Downers Grove, IL USA
[4] Calif Pacific Med Ctr, Geraldine Brush Canc Res Inst, San Francisco, CA 94115 USA
[5] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA
[6] MRC, Mol Biol Lab, Cambridge CB2 2QH, England
关键词
D O I
10.1038/2524
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Gene dosage variations occur in many diseases. In cancer, deletions and copy number increases contribute to alterations in the expression of tumour-suppressor genes and oncogenes, respectively. Developmental abnormalities, such as Down, Prader Willi, Angelman and Cri du Chat syndromes, result from gain or loss of one copy of a chromosome or chromosomal region. Thus, detection and mapping of copy number abnormalities provide an approach for associating aberrations with disease phenotype and for localizing critical genes. Comparative genomic hybridization(1) (CGH) was developed for genome-wide analysis of DNA sequence copy number in a single experiment. In CGH, differentially labelled total genomic DNA from a 'test' and a 'reference' cell population are cohybridized to normal metaphase chromosomes, using blocking DNA to suppress signals from repetitive sequences. The resulting ratio of the fluorescence intensities at a location on the 'cytogenetic map', provided by the chromosomes, is approximately proportional to the ratio of the copy numbers of the corresponding DNA sequences in the test and reference genomes, CGH has been broadly applied to human and mouse malignancies. The use of metaphase chromosomes, however, limits detection of events involving small regions (of less than 20 Mb) of the genome, resolution of closely spaced aberrations and linking ratio changes to genomic/genetic markers. Therefore, more laborious locus-by-locus techniques have been required for higher resolution studies(2-5). Hybridization to an array of mapped sequences instead of metaphase chromosomes could overcome the limitations of conventional CGH (ref, 6) if adequate performance could be achieved. Copy number would be related to the test/reference fluorescence ratio on the array targets, and genomic resolution could be determined by the map distance between the targets, or by the length of the cloned DNA segments. We describe here our implementation of array CGH, We demonstrate its ability to measure copy number with high precision in the human genome, and to analyse clinical specimens by obtaining new information on chromosome 20 aberrations in breast cancer.
引用
收藏
页码:207 / 211
页数:5
相关论文
共 35 条
[1]  
ALBERTSON DG, 1995, CAENORHABDITIS ELEGA, P339
[2]   AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer [J].
Anzick, SL ;
Kononen, J ;
Walker, RL ;
Azorsa, DO ;
Tanner, MM ;
Guan, XY ;
Sauter, G ;
Kallioniemi, OP ;
Trent, JM ;
Meltzer, PS .
SCIENCE, 1997, 277 (5328) :965-968
[3]  
Barlund M, 1997, GENE CHROMOSOME CANC, V20, P372, DOI 10.1002/(SICI)1098-2264(199712)20:4<372::AID-GCC8>3.0.CO
[4]  
2-Z
[5]   A detailed physical and transcriptional map of the region of chromosome 20 that is deleted in myeloproliferative disorders and refinement of the common deleted region [J].
Bench, AJ ;
Aldred, MA ;
Humphray, SJ ;
Champion, KM ;
Gilbert, JGR ;
Asimakopoulos, FA ;
Deloukas, P ;
Gwilliam, R ;
Bentley, DR ;
Green, AR .
GENOMICS, 1998, 49 (03) :351-362
[6]  
Bieche I, 1996, CANCER RES, V56, P3886
[7]   The human CAS (cellular apoptosis susceptibility) gene mapping on chromosome 20q13 is amplified in BT474 breast cancer cells and part of aberrant chromosomes in breast and colon cancer cell lines [J].
Brinkmann, U ;
Gallo, M ;
Polymeropoulos, MH ;
Pastan, I .
GENOME RESEARCH, 1996, 6 (03) :187-194
[8]   Positional cloning of ZNF217 and NABC1:: Genes amplified at 20q13.2 and overexpressed in breast carcinoma [J].
Collins, C ;
Rommens, JM ;
Kowbel, D ;
Godfrey, T ;
Tanner, M ;
Hwang, S ;
Polikoff, D ;
Nonet, G ;
Cochran, J ;
Myambo, K ;
Jay, KE ;
Froula, J ;
Cloutier, T ;
Kuo, WL ;
Yaswen, P ;
Dairkee, S ;
Giovanola, J ;
Hutchinson, GB ;
Isola, J ;
Kallioniemi, OP ;
Palazzolo, M ;
Martin, C ;
Ericsson, C ;
Pinkel, D ;
Albertson, D ;
Li, WB ;
Gray, JW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (15) :8703-8708
[9]   DNA amplifications 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours [J].
Courjal, F ;
Cuny, M ;
Rodriguez, C ;
Louason, G ;
Speiser, P ;
Katsaros, D ;
Tanner, MM ;
Zeillinger, R ;
Theillet, C .
BRITISH JOURNAL OF CANCER, 1996, 74 (12) :1984-1989
[10]   A SIMPLE METHOD OF REDUCING THE FADING OF IMMUNOFLUORESCENCE DURING MICROSCOPY [J].
JOHNSON, GD ;
ARAUJO, GMDN .
JOURNAL OF IMMUNOLOGICAL METHODS, 1981, 43 (03) :349-350